U.S. FDA extends review period for Biogen’s Alzheimer’s drug By Reuters

© Reuters. FILE PHOTO: A sign marks a Biogen facility in Cambridge

(Reuters) – Biogen Inc (NASDAQ:) and partner Eisai Co (OTC:) Ltd said on Friday the U.S. Food and Drug Administration has extended the review period for their experimental Alzheimer’s disease treatment by three months.

Biogen’s shares rose 8% premarket.

The FDA will now decide on the marketing application for the drug, aducanumab, by June 7. An FDA panel in November had voted against approval of the drug.

Biogen submitted the aducanumab marketing application to the FDA in July 2020.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.